Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

249.42USD
2:07pm EDT
Change (% chg)

$-0.67 (-0.27%)
Prev Close
$250.09
Open
$250.69
Day's High
$250.99
Day's Low
$249.09
Volume
244,049
Avg. Vol
569,671
52-wk High
$333.24
52-wk Low
$223.03

Latest Key Developments (Source: Significant Developments)

Biogen acquires Remedy Pharmaceuticals' late-stage drug cirara
Thursday, 18 May 2017 09:00am EDT 

May 18 (Reuters) - Biogen Inc :Biogen acquires Remedy Pharmaceuticals' late-stage drug cirara.Biogen Inc says Biogen made an upfront payment of $120 million to remedy and may also pay additional milestone payments and royalties.Says Biogen made an upfront payment of $120 million to remedy and may also pay additional milestone payments and royalties.  Full Article

Biogen CFO says expects Spinraza adoption to ramp up going forward: Conf Call
Tuesday, 25 Apr 2017 10:09am EDT 

April 25 (Reuters) - Biogen Inc :Biogen says "we are working to add more assetts to our pipeline": Conf Call.Biogen says "underlying tecfidera demand in the U.S. remains stable", and co is well poised to compete against rivals: Conf Call.Biogen says it has maintained global MS market share, despite competition: Conf Call.Biogen says underlying Spinraza demand in U.S. is robust, and numbers increasingly every week: Conf Call.Biogen says 165 plans now cover Spinraza; of all insurance plans, atleast 75 percent cover Spinraza: Conf Call.Biogen Exec says it will be closely watching the performance of roche's new MS drug Ocrevus; Biogen has a royalty deal with Roche for the drug.Biogen CEO sees low single digit growth in MS market in remainder of 2017: Conf Call.Biogen CFO says co will not comment on pricing plans for Biogen's MS drugs: Conf Call.Biogen Exec says "we don't know ultimatley what the long-term durability of Spinraza is...but data so far has been enocuraging": Conf Call.Biogen CFO says Roche's MS drug Ocrevus has negatively impacted Tysabri more than other Biogen drugs: Conf Call.Biogen CFO says its hard to tell the kinetics of Spinraza performance, but expects adoption to ramp up going forward: Conf Call.  Full Article

Biogen Q1 non-GAAP earnings per share $5.20
Tuesday, 25 Apr 2017 06:59am EDT 

April 25 (Reuters) - Biogen Inc ::Biogen reports first quarter 2017 revenues of $2.8 billion.Q1 revenue $2.8 billion versus I/B/E/S view $2.75 billion.Qtrly non-GAAP earnings per share $5.20.Biogen Inc - Q1 tecfidera revenue of $958 million versus. $946 million last year.Biogen Inc - Q1 plegridy revenue of $112 million versus $106 million last year.Qtrly GAAP earnings per share $3.46.Biogen Inc - Q1 avonex revenue of $537 million versus. $564 million last year.Biogen Inc - Q1 tysabri revenue of $545 million versus $477 million last year.Q1 earnings per share view $4.97 -- Thomson Reuters I/B/E/S.  Full Article

Perrigo signs agreement to divest tysabri royalty stream for up to $2.85 billion
Monday, 27 Feb 2017 04:03pm EST 

Perrigo Company Plc : Perrigo signs agreement to divest tysabri® royalty stream for up to $2.85 billion . Perrigo signs agreement to divest tysabri® royalty stream for up to $2.85 billion . Perrigo company plc - deal includes up to $650 million in potential milestone payments based upon future global net sales of tysabri in 2018 and 2020 . Perrigo company plc - transaction is valued at a total consideration of up to $2.85 billion, including $2.2 billion in cash . Perrigo company - royalty pharma will acquire all of perrigo's rights to receive tysabri(® )royalty payments from and after january 1, 2017 . Perrigo company - says royalty pharma will acquire all of perrigo's rights to receive tysabri royalty payments from and after january 1, 2017 . Perrigo company plc - perrigo will also assign to royalty pharma certain information and audit rights under perrigo's existing agreement with biogen . Perrigo - royalty pharma to pay additional payments of $250 million if royalties earned on global sales of tysabri meet specified thresholds during 2018 .Perrigo company- royalty pharma to pay additional payments of $400 million if royalties earned on global net sales of tysabri meet specified thresholds in 2020.  Full Article

Forward Pharma enters license agreement with 2 units of Biogen and other parties
Wednesday, 1 Feb 2017 09:15am EST 

Forward Pharma A/S : Approved entry into settlement, license agreement with 2 wholly owned subsidiaries of Biogen Inc and certain other parties .Forward Pharma - entitled to a non-refundable cash fee of us$1.25 billion within five business days of meeting pursuant to terms of license agreement.  Full Article

Biogen Phase III Alzheimer's trial enrollment ahead of expectations
Thursday, 26 Jan 2017 09:13am EST 

Biogen Inc : Biogen CEO says enrolling of patients for phase III aducanumab Alzheimer's trial ahead of company expectations . Biogen CEO says hoping for swift EU approval of Spinraza for spinal muscular atrophy .Biogen CFO says expects Spinraza revenue uptake to be gradual with majority of 2017 sales in U.S..  Full Article

Biogen qtrly adjusted EPS $ 5.04
Thursday, 26 Jan 2017 06:30am EST 

Biogen Inc : Biogen reports 2016 revenues of $11.4 billion . . Spinraza ( tm ) approved and launched in us for spinal muscular atrophy . Qtrly earnings per share $ 2.99 . Qtrly adjusted earnings per share $ 5.04 . Q4 revenue $2,872 million versus $2,839 million last year . Fy 2017 revenue is expected to be approximately $11.1 to $11.4 billion . 2017 revenue is expected to be approximately $11.1 billion to $11.4 billion . 2017 gaap diluted eps is expected to be between $18.00 and $18.80 . For fy 2017 non-gaap diluted eps is expected to be between $20.45 and $21.25 . Fy2017 earnings per share view $21.02, revenue view $12.08 billion -- Thomson Reuters I/B/E/S . Q4 earnings per share view $4.96, revenue view $2.94 billion -- Thomson Reuters I/B/E/S . Biogen inc- q4 tecfidera revenue of $1,002.0 million versus $992.8 million . Biogen inc says board of directors appoints michel vounatsos as chief executive officer . Biogen inc - q4 avonex revenue of $564 million versus $ 637 million . Biogen inc - q4 tysabri revenue of $473.9 million versus. $480.7 million in the same quarter last year .Biogen inc - q4 plegridy revenue of $125 million versus $103 million in the same quarter last year.  Full Article

Ewopharma partners with Biogen to commercialise Benepali and Flixabi
Monday, 23 Jan 2017 08:43am EST 

Biogen Inc : Ewopharma partners with biogen to commercialise benepali® and flixabi® in central eastern europe . Ewopharma Ag- distribution agreement signed between Ewopharma and Biogen to market and sell co's anti-tumor necrosis factor biosimilars .Ewopharma AG -starting in 2017, Ewopharma will bring Benepali and Flixabi to six countries, Romania, Bulgaria, Croatia, Estonia, Latvia and Lithuania.  Full Article

Biogen spin-off Bioverativ commences when-issued trading of common stock
Thursday, 12 Jan 2017 08:00am EST 

Biogen Inc - : Biogen spin-off Bioverativ commences when-issued trading of common stock . Advised by Nasdaq that common stock for Bioverativ begins trading today, Thursday, January 12, 2017 .Spin-off is expected to be completed on February 1, 2017..  Full Article

Biogen's board approves separation of Bioverativ
Tuesday, 20 Dec 2016 04:01pm EST 

Biogen Inc : Biogen - for every 2 shares of co's common stock held of record on Jan 17 2017, shareholders will receive one share of Bioverativ common stock . Biogen Inc - its board of directors has approved planned spin-off of its hemophilia business, which will be known as Bioverativ Inc .Biogen's board of directors approves separation of Bioverativ and declares special dividend distribution of Bioverativ stock.  Full Article

More From Around the Web

Celgene's multiple sclerosis drug succeeds in late-stage trial

May 22 Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study.